Christine Uy, MD
Endocrinology, Diabetes & Metabolism · Topeka, KSNPI 1669663969
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.7% of the total across 337 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 18.1% — the pattern of someone who eats at a lot of different presentations.
Across 337 payments — averaging $19.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$746
- Amgen$647
- Medtronic$400
- AbbVie$337
- Boehringer Ingelheim$330
- plus $3K from 29 others
What the payments were for
- Speaking & faculty fees$1052%
- Food & beverage$6,56298%
- Education$521%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 69 | $1,215 |
| Lilly USA, LLC | 41 | $746 |
| Amgen(2 entities) | 31 | $647 |
| Medtronic | 22 | $400 |
| AbbVie(2 entities) | 14 | $337 |
| Boehringer Ingelheim | 15 | $330 |
| Corcept Therapeutics | 15 | $301 |
| Abbott | 15 | $297 |
| Amarin Pharma, Inc. | 14 | $268 |
| Amneal Pharmaceuticals LLC | 16 | $260 |
| Dexcom, Inc. | 11 | $250 |
| Radius Health, Inc. | 6 | $152 |
| IBSA Pharma Inc. | 8 | $150 |
| Insulet Corporation | 5 | $139 |
| Sanofi-aventis U.S. LLC | 9 | $127 |
| GRT US Holding, Inc. | 1 | $125 |
| AstraZeneca(2 entities) | 7 | $110 |
| Sanofi | 1 | $105 |
| Nevro Corp. | 3 | $86 |
| BETA Bionics, Inc. | 4 | $86 |
| Ascendis Pharma Endocrinology Inc | 4 | $76 |
| Merck | 4 | $74 |
| Xeris Pharmaceuticals, Inc. | 3 | $53 |
| Novartis | 3 | $50 |
| Tandem Diabetes Care, Inc. | 2 | $46 |
| Kyowa Kirin, Inc. | 2 | $45 |
| Neurocrine Biosciences, Inc. | 2 | $44 |
| Astellas Pharma US Inc | 2 | $41 |
| Sequel Med Tech, LLC | 2 | $36 |
| Rhythm Pharmaceuticals, Inc. | 1 | $30 |
| Ascensia Diabetes Care US Inc. | 1 | $25 |
| Ultragenyx Pharmaceutical Inc. | 1 | $23 |
| Averitas Pharma Inc. | 1 | $19 |
| Bayer | 1 | $15 |
| Antares Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DALVANCE$125
- Qutenza$125
- KRYSTEXXA$125
- SOLIQUA 100/33$105
How this compares
$6,719 in reported general payments places this provider in the 70th percentile of 50 endocrinology, diabetes & metabolism providers in Kansas.
See all endocrinology, diabetes & metabolism providers in Kansas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 211 | $296,567 |
| MounjaroTirzepatide | 147 | $218,882 |
| JardianceEmpagliflozin | 50 | $46,247 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 26 | $39,766 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 40 | $37,502 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 14 | $28,397 |
| LyumjevInsulin Lispro-Aabc | 19 | $27,206 |
| FarxigaDapagliflozin Propanediol | 27 | $26,698 |
| TrulicityDulaglutide | 15 | $22,786 |
| TradjentaLinagliptin | 15 | $21,806 |
| Tresiba Flextouch U-200Insulin Degludec | 21 | $21,582 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 24 | $20,039 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 12 | $18,651 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 16 | $17,365 |
| JanuviaSitagliptin Phosphate | 16 | $13,645 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $1,215 | $305,932225 claims |
| Lilly USA, LLCMounjaro, Lyumjev, Trulicity, Insulin Lispro | $746 | $269,585192 claims |
| Boehringer IngelheimJardiance, Tradjenta, Trijardy Xr, Synjardy Xr | $330 | $104,07093 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $127 | $39,76626 claims |
| AstraZenecaFarxiga | $110 | $26,69827 claims |
| MerckJanuvia | $74 | $13,64516 claims |
| AbbVieSynthroid | $337 | $2,74434 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $260 | $1,731206 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 50 endocrinology, diabetes & metabolism providers in Kansas.
Other endocrinology, diabetes & metabolism in Topeka
- Susan BrianTopeka$9K
- Alan WynneTopeka$8K
- Bahaa Abu BakrTopeka$3K
- Jeffrey FajardoTopeka$2K
- Su Ah BaeTopeka$2K
- Francisco CorreaTopeka$2K
- Noor AddasiTopeka$741
- Dana AwadTopeka$340
- Vidita DivanTopeka$276
- Kaitlin DitchTopeka$249
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.